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Abstract 
This study examined age group differences across adulthood in comorbid conditions, mental health 
and cognitive function in people with fibromyalgia. Participants completed an online survey about 
how fibromyalgia affects everyday life. Chi square analyses were conducted to examine associations 
between age groups and 1) comorbid conditions and 2) anxiety and depression severity. ANOVA 
analyses examined age group differences on aspects of self-report cognitive function. The greatest 
prevalence of comorbid conditions was found in middle adulthood. Early adulthood was associated 
with more cases of severe anxiety with the lowest number of cases being in the oldest age group. 
Middle adulthood was associated with worse self-report pain compared to the youngest age group. 
Older adults showed better self-report cognitive function compared to younger adults. Distinct age 
profiles based on comorbid conditions, mental health and symptom severity across adulthood in 
fibromyalgia have been demonstrated.  
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Comorbid conditions, mental health and cognitive functions are age-related during adulthood in 
patients with fibromyalgia 
 
Fibromyalgia is a chronic condition associated with pain, disturbed sleep, fatigue, cognitive 
impairment, depression and anxiety (Lawson, 2017). The prevalence of fibromyalgia varies across 
adulthood. In the US population the prevalence of fibromyalgia was reported as lowest in the 18-29 
year old group and highest in the 50 to 59 year old group (Walitt et al., 2015). Fibromyalgia is often 
diagnosed in middle adulthood (Cronan et al., 2002), although there are reports of juvenile 
fibromyalgia (Kashikar-Zuck et al., 2016). Chronic pain in late adolescence and early adulthood could 
negatively impact education and employment, independence and peer and romantic relationships 
(Rosenbloom et al., 2017). Patients in early adulthood who expect to have an active lifestyle may 
perceive a chronic health condition as more disruptive compared to someone in later adulthood 
(Cronan et al., 2002). Thus, the condition may have different effects on quality of life depending on 
the life stage of an individual. 
 
Historically, health has been viewed using the biomedical model. A criticism of the medical model is 
that psychological and social factors are neglected with these factors being included in the 
biopsychosocial model (Engel, 1980). More recently, Lehman et al., (2017) proposed the dynamic 
biopsychosocial model that incorporates biological, psychological, interpersonal and contextual 
factors affecting health. A key aspect of this model is that the factors interact over time. The 
dynamic biopsychosocial model includes notions from Bronfenbrenner’s ecological model (1986) 
where the microsystem, mesosystem and exosystem influence health. The dynamic biopsychosocial 
model applies the lifespan approach to health and indicates that different factors may be more 
important at certain developmental stages (Lehman et al., 2017).  
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Some studies have examined age group differences in fibromyalgia symptoms, mental health and 
quality of life. Cronan et al., (2002) compared young (20-39 year olds), middle-aged (40-59 year olds) 
and older adults (60 to 85 year olds) on self-reported pain and the effects of fibromyalgia on 
everyday life, sleep, depression and wellbeing. Participants in the older group reported significantly 
less pain, depression, impact of illness and better sleep quality compared to younger and middle-
aged groups. These results may be explained by older adults attributing fibromyalgia symptoms to 
normal aging (Jiao et al., 2014). There were no age group differences in psychosocial variables of 
coping styles, self-efficacy and helplessness indicating that these did not influence fibromyalgia 
improvements with age. A limitation is that the direction of relationship between mood and health 
could not be ascertained in the cross-sectional design of the study (Cronan et al., 2002). Another 
study found that younger (≤39 years) and middle-aged groups (40-59 years) reported poorer 
symptom effects on daily functioning and poorer quality of life compared to the older group aged 60 
years and over (Jiao et al., 2014).  
 
Contrasting results were reported in a study about anxiety, depression and alexithymia in 
fibromyalgia patients in early (≤ 35 years), middle (>35 and <65 years) and older adulthood (≥65 
years). The younger age group reported significantly lower anxiety, depression and alexithymia 
scores compared to the oldest age group, indicating that early adulthood was associated with more 
optimal functioning relative to older adulthood (Peñacoba Puente et al., 2013). Therefore, previous 
research has found contrasting results in terms of age group differences in fibromyalgia. Inconsistent 
findings may be due to studies having different cut-off ages for early, middle and older adulthood. 
Furthermore, participants’ symptom severity and time since diagnosis may vary between studies.  
 
Dyscognition, impaired cognitive function in fibromyalgia, is part of a recently developed multi-
dimensional diagnostic framework (Arnold et al., 2019). Moriarty et al., (2011) proposed a model of 
pain-related cognitive impairment based on pain leading to limited cognitive resources, altering 
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neuroplasticity and dysregulating neurochemistry. There is convergent evidence of dyscognition 
from performance based (Muñoz Ladrón de Guevara et al., 2018) and subjective measures (Williams 
et al., 2011). A meta-analysis showed fibromyalgia was related to poorer performance on cognitive 
function tasks compared to control groups (Bell et al., 2018). There were greatest group differences 
for inhibitory control, medium effect sizes for processing speed, short- and long-term memory and 
updating with a smallest effect size for set shifting. Existing research has showed executive function 
impairments in fibromyalgia in adults aged 50 and over (Cherry et al., 2014), but there is a lack of 
research on fibromyalgia and cognitive function across the whole adult lifespan. 
 
Previous research indicates the presence of comorbid conditions in fibromyalgia. A study examined 
hospital records in Turkey and found that 67.8% of the sample of patients with fibromyalgia were 
diagnosed with one or more comorbid conditions, with cardiovascular, endocrine and mental 
disorders being the most prevalent (Bilge et al., 2018). Häuser et al., (2018) suggested a treatment 
approach based on subgroups characterised by pain, mental health and comorbid conditions. 
Therefore, it is important to ascertain comorbid conditions affecting patients with fibromyalgia so 
that awareness may inform diagnosis and treatment options. 
 
Purpose 
The present study examined self-report comorbid conditions, fibromyalgia symptoms and cognitive 
function in participants with fibromyalgia across the adult lifespan. Previous studies have split 
adulthood into early, middle and late adulthood. The present study extends previous research by 
analysing group differences in more fine-grained age groups.  
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Method 
A qualitative interview study (Ashe et al., 2017) informed the development of the online survey. The 
survey assessed symptom severity, mood, cognitive impairment and comorbid conditions have not 
previously been assessed across adulthood in people with fibromyalgia using fine grained age groups 
Research indicates fibromyalgia is associated with depression, anxiety and cognitive impairment 
(Bell et al., 2018) so pre-existing measures of symptom severity, mood and cognitive impairment 
were included in the survey. Fibromyalgia is associated with comorbid conditions (Bilge et al., 2018), 
although previous research has not always assessed these, and comorbid conditions could influence 
treatment success. The survey was advertised from January to April 2016 by fibromyalgia charities, 
networks and support groups. Using data from the online survey we have published a qualitative 
paper about perceived causes of fibromyalgia (Furness et al., 2018), a quantitative study about the 
effectiveness of pharmacological and non-pharmacological treatments (Taylor et al., 2019) and a 
qualitative paper about attitudes to physiotherapy (Furness et al., 2019). This research received 
ethical approval from Sheffield Hallam University Research Ethics Committee (FREC/SW/125-FUR). 
Completion and submission of the online survey was taken as implied consent. 
 
Design 
This study used a cross-sectional design to compare comorbidities, mental health and symptom 
severity across six age groups in adulthood. 
 
Participants 
Inclusion criteria for participants were to be aged 18 or over with an official diagnosis of 
fibromyalgia. Nine hundred and forty-one participants aged between 18 and 87 years (M = 47.70, SD 
= 12.09) completed the online survey. 
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Measures 
The online survey included the following measures: 
Fibromyalgia symptoms Participants completed the ‘symptoms of sensory reactivity’ and ‘symptoms 
of pain and consequences’ scales from the Comprehensive Rating Scale for Fibromyalgia (CRSFS; 
López-Pousa et al., 2013). Participants considered symptoms over the previous 2 weeks and selected 
a response from the following options: never/once, several days, more than half of the days and 
almost every day. There were 6 items assessing sensory reactivity symptoms (e.g. joint discomfort 
that has restricted movement) and seven items assessing pain and consequences (e.g. general 
tiredness that has prevented you from performing your daily activities). Possible scores ranged 
between 0 to 54 for the sensory reactivity subscale and 0 to 63 for the pain and consequences 
subscale. Higher scores indicated greater sensory reactivity and consequences of pain. The subscales 
showed good reliability (Cronbach’s α for sensory reactivity = 0.89 and Cronbach’s α for pain and 
consequences = 0.87). 
Anxiety and depression Participants completed the Hospital Anxiety and Depression Scale (HADS; 
Zigmond & Snaith, 1983) by selecting a response from four options about how they had felt in the 
past week. Seven items assessed anxiety (e.g. worrying thoughts go through my mind) and seven 
items assessed depression (e.g. I look forward with enjoyment to things). Possible scores were 
between 0 and 21 with scores categorised as normal (0-7), mild (8-10), moderate (11-15) and severe 
(16-21; Snaith & Zigmond, 1994). The separate scales were reliable (Cronbach’s α anxiety = 0.84 and 
Cronbach’s α depression = 0.83). 
Cognitive impairment Participants completed the Multidimensional Inventory of Subjective 
Cognitive Impairment (MISCI; Kratz et al., 2015) by rating 10 statements using a 5 point Likert scale 
about their cognitive function in the previous 7 days. Two items assessed mental clarity, memory, 
attention, executive function and language. An example of a mental clarity item is ‘I have been able 
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to think clearly without extra effort.’ Possible scores ranged from 10 to 50 with higher scores 
indicating better self-report cognitive function and lower impairment. The reliability (Cronbach’s α = 
0.66) was below the acceptable value of 0.7 that Nunnally (1978) recommended. 
Self-report comorbid conditions Participants selected whether they had experienced any of the 
following conditions: chronic fatigue, arthritis, irritable bowel syndrome (IBS), thyroid, diabetes, 
circulation disorders, coeliac disease, migraine, mitochondrial dysfunction, hypermobility, anxiety 
and depression. 
 
Data analysis 
Chi square analyses examined associations between age groups and the presence of comorbid 
conditions. Further chi square analyses were conducted to examine associations between age group 
and classification of anxiety and depression (normal, mild, moderate and severe). ANOVAs were 
conducted on MISCI total scores and subscale scores to examine whether age group had a significant 
effect on cognitive function. If the ANOVA was significant then pairwise comparisons with Bonferroni 
adjustment were conducted. ANOVAs were conducted on CRSFS sensory reactivity and pain and 
consequences scores to examine whether age group had a significant effect on symptom severity. 
 
Results 
Sample characteristics 
The sample was divided into the age groups: 18-29 (n = 80), 30-39 (n = 136), 40-49 (n = 277), 50-59 
(n = 309), 60-69 (n = 109), and 70-87 years (n = 27). Three participants did not report age data and 
were excluded from analyses. Eight hundred and ninety-two female participants and 45 male 
participants completed the survey with three participants not reporting gender and one participant 
identifying as mixed gender. Nine hundred and two participants reported ethnicity as white, 15 
participants reported mixed ethnicity, followed by 9 participants identifying as Asian and 6 as black. 
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One participant reported being from the following ethnicities: Greek, Irish / Greek Cypriot, middle 
eastern and Portuguese. Four participants did not report ethnicity. 
 
Comorbid conditions by age group 
Table 1 shows frequencies and chi square results for associations between comorbid conditions and 
age groups. There was an association between age groups and the presence of arthritis with the 
highest prevalence in the 50 to 59 year age group and lowest prevalence in the 18 to 29 year age 
group. There was also an association between thyroid comorbidity and age groups. Similarly, the 
highest prevalence of thyroid conditions was in the 50 to 59 year age group whereas the lowest 
prevalence was in the oldest age group. Chi square results showed an association between age 
groups and diabetes with the 50 to 59 year age group reporting the highest prevalence. There were 
fewer than 5 reports of diabetes in the youngest and oldest age groups. The association between 
age groups and migraine was significant, with the 60 to 69 year age group reporting the most 
migraines and the oldest age group reporting the fewest migraines. Chi square results showed an 
association between age groups and comorbid hypermobility with the highest prevalence in the 50 
to 59 year age group and lowest prevalence in the oldest age group. There was no association 
between age groups and the presence of IBS, circulation disorders, coeliac disease, mitochondrial 
dysfunction, or chronic fatigue. 
 
Overall, the comorbidity data indicates higher reports of comorbid conditions in the 50 to 59 year 
old group for arthritis, thyroid, diabetes and hypermobility and for migraines in the 60 to 69 year old 
age group. The youngest age group reported the lowest prevalence of arthritis and diabetes. The 
oldest age group reported the lowest prevalence of thyroid conditions, diabetes, migraines and 
hypermobility. This data suggests there are comorbid conditions associated with particular age 
groups across adulthood in fibromyalgia.  
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HADS Anxiety and Depression severity by age group 
Table 2 shows frequencies of anxiety and depression severity by age group and results from chi 
square analyses. There was an association between age group and HADS anxiety severity, but no 
association between age group and HADS depression severity. 43% of participants in the 18 to 29 
year age group were in the severe anxiety category compared to the oldest age group where 15% of 
participants were in the severe anxiety category.  
 
Cognitive function by age group 
There was a significant effect of age on overall cognitive function, F (5, 913) = 10.00, p < 0.001, with 
the 70 to 87 year age group scoring significantly higher, indicating better cognitive function, 
compared to all other age groups (p < 0.01) (Table 3). The 60 to 69 year group also scored 
significantly higher compared to the 30 to 39, 40 to 49 and 50 to 59 year groups (p ≤ 0.036). There 
was also a significant effect of age on mental clarity, F (5, 913) = 9.67, p < 0.001, with the oldest age 
group scoring significantly higher, indicating better mental clarity, compared to all younger age 
groups (p ≤ 0.01). Similarly, the 60 to 69 year group scored significantly higher, indicating better 
mental clarity, compared to younger age groups (p ≤ 0.037). Similarly, there was a significant effect 
of age on memory, F (5, 913) = 6.93, p < 0.001, with the oldest age group scored significantly higher, 
indicating better memory, compared to all younger groups (p < 0.01). ANOVA results showed a 
significant effect of age on attention, F (5, 913) = 9.58, p < 0.001. The 60 to 69 year group scored 
significantly higher, indicating better attention, relative to the 30-39, 40-49, 50-59 and 70-87 year 
groups (all p < 0.05). The oldest age groups scored significantly higher compared to all other age 
groups (p < 0.01). There was no effect of age on executive function, F (5, 913) = 0.74, p = 0.597, or 
language, F (5, 913) = 0.78, p = 0.562. 
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Overall, results indicate that older age groups performed better, compared to younger groups, on 
overall self-report cognitive function, mental clarity, memory and attention. There was no effect of 
age on self-report executive function or language. 
 
Symptom severity 
There was a significant effect of age on sensory reactivity scores, F (5, 900) = 3.42, p = 0.005 (Table 
4). The 40-49 (p = 0.024) and 50-59 (p < 0.01) year groups scored significantly higher, indicating 
worse symptoms, compared to the 18-29 year age group. There was no effect of age group on pain 
and consequences scores, F (5, 884) = 1.46, p = 0.199.  
 
Discussion 
Comorbid conditions, mental health and cognitive function across adulthood were examined in 
people with fibromyalgia. The results of this study indicate that distinct age profiles across 
adulthood exist in people with fibromyalgia. Early adulthood (18 to 29 year age group) was 
associated with the lowest prevalence of arthritis and diabetes, although the youngest age group 
had the lower pain and consequences scores and highest prevalence of severe anxiety compared to 
40-49 and 50-59 year groups. The 40-49 and 50-59 year groups scored higher on pain and 
consequences compared to the youngest age group. The 50-59 year age group was also 
characterised by the highest reports of arthritis, thyroid, diabetes and hypermobility. The 60-69 year 
age group was associated with the highest report of migraine and overall less impaired self-report 
cognitive function compared to the 30-39, 40-49 and 50-59 year age groups. The 60-69 year group 
reported less impaired mental clarity relative to younger groups and less impaired attention 
compared to 30-39, 40-49, 50-59 and 70-87 year groups. The oldest age group (70-87 year) was 
characterised by the lowest prevalence of thyroid conditions, diabetes, migraine and hypermobility. 
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There were fewer reports of severe anxiety and less impaired overall cognitive function, mental 
clarity, memory and attention in the oldest age group compared to younger groups.  
 
These results support previous research showing that older adulthood is associated with better 
mental health and lower symptom severity in people with chronic pain or fibromyalgia (Cronan et 
al., 2002; Jiao et al., 2014; Wittink et al., 2006). A literature review found reports of high levels of 
resilience in some studies of older adults (MacLeod et al., 2016) and resilience was associated with 
lower healthcare utilization and improved self-rated health (Ezeamama et al., 2016). In a sample of 
people with fibromyalgia, resilience was found to increase positive affect and decrease negative 
affect which in turn improved fibromyalgia symptoms (McAllister et al., 2015).  
 
The finding of comorbid conditions, mental health and pain varying over the adult lifespan may be 
applied to the dynamic biopsychosocial model (Lehman et al., 2017). For example, greater pain and 
comorbid conditions being more often reported in middle adulthood compared to early adulthood 
aligns with the biological dynamic component of the model. Furthermore, the finding of severe 
anxiety being more prevalent in early adulthood and least prevalent in the oldest age group supports 
the psychological dynamics component of the model. The present analyses did not include 
interpersonal dynamics and this aspect of the model is the most frequently omitted part (Suls & 
Rothman, 2004). Nevertheless, there is existing evidence of how biological, psychological and social 
factors interact affecting health in chronic pain conditions including fibromyalgia (Adams & Turk, 
2015; Furness et al., 2018).  
 
There were significant associations between comorbid conditions and age groups in this sample of 
people with fibromyalgia. These data indicate that age 50 to 59 years in middle adulthood is a risk 
factor for poorer outcomes in terms of a higher prevalence of certain comorbid conditions, higher 
pain severity and poorer self-report cognitive functions. Lifestyle factors, including poor diet, 
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elevated body mass index and smoking, may contribute to health conditions such as chronic 
widespread pain and comorbid conditions of cancer and cardiovascular disease (VanDenKerkhof et 
al., 2011). The menopausal transition is also an important factor to consider in this predominantly 
female sample where the 50 to 59 year group was the largest group compared to other age groups. 
The average age of menopause has been reported as 51 years in the UK (Sarri et al., 2015) and 
menopausal transition has been associated with short-term cognitive function changes (Morgan et 
al., 2018). It is important to also treat comorbid conditions because this may improve quality of life 
(Bilge et al., 2018). NICE guidance indicates that HRT and cognitive behavioural therapy may assist 
with low mood or anxiety associated with the menopausal transition (Sarri et al., 2015) so these 
should be recommended if psychological symptoms of menopausal transition are a comorbid 
condition.  
 
Fibromyalgia should be examined if a patient is presenting with pain and fatigue; if undiagnosed and 
untreated, comorbid fibromyalgia may result in incorrect treatment (Fitzcharles et al., 2018). The 
finding of distinct age profiles based on comorbid conditions, mental health and severity of 
symptoms supports the conceptualisation of subgroups in fibromyalgia. Häuser et al., (2018) 
suggested subgroups based on pain, mental health and comorbidities, highlighting the importance of 
identifying the subgroups to enable individualised treatment approaches. 
 
Age group comparisons of self-report cognitive function indicated that older age groups performed 
better, compared to younger groups, on overall self-report cognitive function, mental clarity, 
memory and attention. There was no effect of age on self-report executive function or language. The 
assessment of executive function may be beneficial to younger adults with fibromyalgia because 
interventions may then be employed. Baker et al., (2017) identified several approaches aimed at 
improving cognitive function in chronic pain including psychoeducation, cognitive training, 
psychological therapy, medication optimisation and physical activity. The current study assessed 
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self-report cognitive functions with the MISCI. Kratz et al., (2015) reported excellent internal 
consistency, although in the present study internal consistency was below the acceptable threshold. 
In the present study if either ‘trouble planning the steps of a task’ or ‘harder than usual to express 
myself’ were deleted this resulted in an acceptable reliability. Herreen and Zajac (2018) questioned 
the use of self-report cognitive function measures after finding that self-report cognitive function 
scores were better predicted by personality scores than performance based cognitive function 
measures. It should also be noted that general fatigue was not assessed and Williams et al., (2011) 
found that fatigue positively correlated with perceived cognitive dysfunction. 
 
Future research should employ a sequential design examining trajectories across different age 
groups to assess developmental changes and identify treatments that may be beneficial at different 
stages of development (Peñacoba Puente et al., 2013). There is evidence of divergent trajectories 
with regards to pain and depression in participants with juvenile-onset fibromyalgia followed up 
after 8 years (Black et al., 2019). Research using performance based executive function tasks and 
including a mood assessment would further understanding of how affect and cognitive function are 
related in fibromyalgia.  
 
In conclusion, the present study indicates age profiles based on comorbid conditions, mental health, 
cognitive functions and symptom severity across adulthood in fibromyalgia. Fibromyalgia 
assessment in the future should consider the developmental stage of people to enable identification 
of possible subgroups and the formulation of individualised treatment approaches. 
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Table 1. Comorbid conditions by age group  
Condition 18-29 years 
n (%) 
30-39 years 
n (%) 
40-49 years 
n (%) 
50-59 years 
n (%) 
60-69 years 
n (%) 
70-87 years 
n (%) 
2 
Irritable Bowel Syndrome 52.0 (5.5)  98.0 (10.4)  202.0 (21.5) 223.0 (23.8) 84.0 (9.0) 13.0 (1.4) 10.93 
Arthritis 9.0 (1.0)  33.0 (3.5) 104.0 (11.1) 169.0 (18.0) 67.0 (7.1) 17.0 (1.8) 92.71** 
Circulation disorders 28.0 (3.0)  39.0 (4.2)  92.0 (9.8) 101.0 (10.8) 33.0 (3.5) 6.0 (0.6) 2.61 
Thyroid 5.0 (0.5)  18.0 (1.9) 49.0 (5.2) 78.0 (8.3) 26.0 (2.8) 7.0 (0.7) 21.44** 
Coeliac 6.0 (0.6)  < 5.0 11.0 (1.2) 15.0 (1.6) < 5.0 < 5.0 4.64 
Diabetes < 5.0 6.0 (0.6) 22.0 (2.3) 36.0 (3.8) 9.0 (1.0) < 5.0 15.47** 
Migraine 50.0 (5.3)  83.0 (8.8) 190.0 (20.3) 172.0 (18.3) 59.0 (6.3) 6.0 (0.6) 28.73** 
Hypermobility 31.0 (3.3)  37.0 (3.9) 45.0 (4.8) 56.0 (6.0) 17.0 (1.8) < 5.0 30.99** 
Mitochondrial dysfunction < 5.0 < 5.0 8.0 (0.9) 6.0 (0.6) < 5.0 < 5.0 2.84 
Chronic fatigue 59.0 (6.3)  103.0 (11.0) 210.0 (22.4) 232.0 (24.7) 78.0 (8.3) 15.0 (1.6) 5.99 
*p < 0.05, **p < 0.01 
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Table 2. Comorbid anxiety and depression severity by age group 
Severity of 
condition 
18-29 years 
n (%) 
30-39 years 
n (%) 
40-49 years 
n (%) 
50-59 years 
n (%) 
60-69 years 
n (%) 
70-87 years 
n (%) 
2 
Anxiety 
Normal 
Mild 
Moderate 
Severe 
 
10.0 (1.1) 
16.0 (1.7) 
20.0 (2.2) 
34.0 (3.7) 
 
17.0 (1.8) 
23.0 (2.5) 
44.0 (4.7) 
50.0 (5.4) 
 
53.0 (5.7) 
61.0 (6.6) 
90.0 (9.7) 
69.0 (7.4) 
 
60.0 (6.5) 
73.0 (7.8) 
103.0 (11.1) 
72.0 (7.7) 
 
30.0 (3.2) 
25.0 (2.7) 
33.0 (3.5) 
21.0 (2.3) 
 
11.0 (1.2) 
6.0 (0.6) 
5.0 (0.5) 
< 5.0 
38.76** 
Depression 
Normal 
Mild 
Moderate 
Severe 
 
20.0 (2.2) 
21.0 (2.3) 
25.0 (2.7) 
14.0 (1.5) 
 
35.0 (3.8) 
27.0 (2.9) 
43.0 (4.6) 
29.0 (3.1) 
 
64.0 (6.9) 
65.0 (7.0) 
88.0 (9.5) 
56.0 (6.0) 
 
66.0 (7.1) 
79.0 (8.5) 
98.0 (10.5) 
65.0 (7.0) 
 
30.0 (3.2) 
31.0 (3.3) 
30.0 (3.2) 
18.0 (1.9) 
 
12.0 (1.3) 
9.0 (1.0) 
< 5.0 
< 5.0 
17.04 
**p < 0.01 
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Table 3. Descriptive statistics for total MISCI and subscale scores  
Aspects of 
cognitive function 
18-29 years 
n = 76 
M (SD) 
30-39 years 
n = 133 
M (SD) 
40-49 years 
n = 270 
M (SD) 
50-59 years 
n = 305 
M (SD) 
60-69 years 
n = 109 
M (SD) 
70-87 years 
n = 26 
M (SD) 
F 
Total  23.42 (5.65) 23.32 (5.86) 23.34 (5.48) 23.66 (5.07) 25.50 (5.62) 30.19 (5.23) 10.00** 
Mental clarity 4.09 (2.15) 4.18 (2.02) 4.17 (2.00) 4.37 (1.89) 5.05 (2.06) 6.54 (2.37) 9.67** 
Memory 3.97 (2.03) 3.86 (2.05) 3.75 (1.92) 3.71 (1.78) 4.22 (2.03) 5.85 (1.83) 6.93** 
Attention 3.96 (1.96) 3.86 (1.95) 3.92 (1.91) 3.97 (1.83) 4.67 (2.11) 6.23 (1.99) 9.58** 
Executive function 5.74 (1.26) 5.71 (1.15) 5.73 (1.06) 5.85 (1.17) 5.84 (1.04) 5.58 (0.76) 0.74 
Language 5.66 (0.92) 5.71 (0.79) 5.77 (0.80) 5.76 (0.83) 5.72 (0.89) 6.00 (0.80) 0.78 
*p<0.05, **p < 0.01 
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Table 4. Descriptive statistics for CRSFS symptom severity by age group 
CRSFS subscale 18-29 years 
M (SD) 
30-39 years 
M (SD) 
40-49 years 
M (SD) 
50-59 years 
M (SD) 
60-69 years 
M (SD) 
70-87 years 
M (SD) 
F 
 
 n = 75 n = 131 n = 268 n = 299 n = 107 n = 26  
CRSFS Sensory 
reactivity 
32.28 (11.79) 34.90 (10.82) 36.58 (10.18) 37.06 (10.28) 34.64 (9.75) 34.69 (10.18) 3.42** 
 n =74 n = 127 n = 263 n = 295 n = 105 n = 26  
CRSFS Pain and 
Consequences 
39.59 (12.40) 41.61 (11.21) 41.90 (10.90) 41.72 (11.51) 40.50 (10.73) 36.92 (12.98) 1.46 
**p < 0.01 
 
 
 
 
 
